Show simple item record

dc.contributor.authorAttard, G
dc.contributor.authorBrown, LC
dc.contributor.authorClarke, N
dc.contributor.authorMurphy, L
dc.contributor.authorCross, W
dc.contributor.authorJones, R
dc.contributor.authorGillessen, S
dc.contributor.authorRussell, JM
dc.contributor.authorCook, A
dc.contributor.authorBowen, J
dc.contributor.authorLydon, A
dc.contributor.authorPedley, ID
dc.contributor.authorParikh, O
dc.contributor.authorChowdhury, S
dc.contributor.authorMalik, Z
dc.contributor.authorMatheson, D
dc.contributor.authorParker, C
dc.contributor.authorSydes, MR
dc.contributor.authorParmar, MK
dc.contributor.authorJames, ND
dc.date.accessioned2021-10-26T09:31:26Z
dc.date.available2021-10-26T09:31:26Z
dc.date.issued2021-09-01
dc.identifier.citationAttard, G., Brown, L.C., Clarke, N. et al. (2021) Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Annals of Oncology, 32, S5, S1298.en
dc.identifier.issn0923-7534en
dc.identifier.doi10.1016/j.annonc.2021.08.2098en
dc.identifier.urihttp://hdl.handle.net/2436/624420
dc.descriptionThis is an accepted manuscript of an abstract published by Elsevier in Annals of Oncology on 01/09/2021, available online: https://doi.org/10.1016/j.annonc.2021.08.2098 The accepted version of the publication may differ from the final published version.en
dc.formatapplication/pdfen
dc.languageen
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttps://www.annalsofoncology.org/article/S0923-7534(21)04402-1/fulltext#relatedArticlesen
dc.subjectgenitourinary tumoursen
dc.subjectprostate canceren
dc.titleAbiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocolen
dc.typeOtheren
dc.identifier.eissn1569-8041
dc.identifier.journalAnnals of Oncologyen
dc.date.updated2021-10-22T10:15:23Z
dc.date.accepted2021-07-20
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW26102021DMen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2021-10-26en
dc.source.volume32
dc.source.beginpageS1298
dc.source.endpageS1298
dc.description.versionPublished version
refterms.dateFCD2021-10-26T09:29:27Z
refterms.versionFCDAM
refterms.dateFOA2021-10-26T09:31:27Z


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Attard_et_al_Abiraterone_aceta ...
Size:
623.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/